Fresenius Kabi Slapped With Infringement Suit Over US Denosumab Biosimilars
Amgen Alleges Infringement Of Dozens Of Patents; Previously Sued Trio Of Sponsors
Fresenius Kabi is facing up to a patent-litigation suit over its proposed biosimilars to Amgen’s Prolia/Xgeva brands – although a prior lawsuit involving biosimilar sponsor Sandoz concluded with a settlement agreement.
